An observational study in Meningioma of Brain, Meningioma and Brain Tumor, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by University of California, San Francisco · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.
Among the 129 studies in Meningioma with a site in United States, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 5 that started in 2026, is one of 14 observational ones, reaches primary completion later than 36 of the 37 other live ones, and was the 126th registered.
256 studies on the registry are indexed under Meningioma; 86 are open to participants now.
Browse Meningioma studies →27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18+
Eben Rosenthal · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
Joshua Palmer · Sites in United States
Ages 18+
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
129 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 55 · Phase 3 6 · Phase 4 2
First in 1992; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 112 across 57 observational studies indexed under Meningioma.
Median enrollment 30 across the 107 interventional studies, 106 across the 14 observational. Of the 82 that completed or were terminated, 31 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 129 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 2 studies filed under Meningioma — fewer than ten, so there is no comparison to draw.
14 of the studies in Meningioma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03180268Phase 3NRG OncologyObservation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | 2027-06-15 |
| NCT05425004Baptist Health South FloridaCabozantinib for Patients With Recurrent or Progressive Meningioma | 2026-12 |
| NCT04087902Ohio State UniversityLong-Term Longitudinal QoL in Patients Undergoing EEA | 2026-12-31 |
| NCT07150806Joshua PalmerRYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | 2026-12-31 |
| NCT06377371Weill Medical College of Cornell UniversityFeasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE | 2027-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 129 studies in Meningioma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Meningiomas are the most common primary brain tumor, and some groups are diagnosed with higher-grade tumors and have clinically worse outcomes. This study investigates social determinants of health and individual risk factors that may be associated with meningioma.
PRIMARY OBJECTIVES:
I. To assess prevalence and distribution of social and structural determinants of health (SSDH) among meningioma patients.
II. To assess disparities in SSDH among meningioma patients of different races.
OUTLINE: This is an observational study.
Participants will complete a survey and have their medical records reviewed.
Adult participants receiving care at the University of California, San Francisco who have been diagnosed with meningioma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients who have been diagnosed with a meningioma will be asked to complete a one-time survey, which will take roughly 20 minutes to complete. Participants will also have medical records reviewed to capture additional data relating to the participants medical history.
Behavioral: Questionnaire · Other: Medical Record Review
A questionnaire will be administered in person or online
Medical records will be reviewed for study specific data collection
Identifying potential social and structural determinants of health (SSDH)
The prevalence of SSDH factors such as race and ethnicity, birthplace, relationship status, sexual orientation/gender identity, education level, socio-economic status, access to care, reproductive/menstrual history, health factors and medication use, chemical and radiation exposure, smoking history, and perceived stress for participants with meningioma will be analyzed using multilevel logistic and linear models accounting for geographical clustering.
Time frame: Up to 5 years
Distribution of social and structural determinants of health
The distribution of SSDH factors across racial groups will be analyzed using multilevel logistic and linear models accounting for geographical clustering.
Time frame: Up to 5 years
Identify disparities in social and structural determinants of health (SSDH)
Disparities of SSDH factors across racial groups will be analyzed using multilevel logistic and linear models accounting for geographical clustering.
Time frame: Up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2031, 59 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →